Frontiers reaches 6.4 on Journal Impact Factors

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Med. | doi: 10.3389/fmed.2018.00046

Establishment of the World Health Organization 1st International Standard for Factor XII, Plasma, Human

 Helen Wilmot1*, Jason Hockley2,  Peter Rigsby2 and  Elaine Gray1
  • 1Haemostasis Section, National Institute for Biological Standards and Control (NIBSC), United Kingdom
  • 2Biostatistics Group, National Institute for Biological Standards and Control (NIBSC), United Kingdom

Until recently, the role of factor XII (FXII) in haemostasis was not considered to be important since patients with FXII deficiency do not present with bleeding. The activation of FXII by agents including mast cells and platelet polyphosphates suggests it may have a role in thrombogenesis. Inhibition of FXII therefore presents an option for antithrombotic therapy and antibodies and inhibitors are already in development. Assays for FXII will be required to support these technologies and an international standard (IS) for FXII would be useful for the development of these methods and for clinical monitoring of patients.
The purpose of this study was to develop an International Standard for FXII, with values for functional activity (FXII:C) and antigen (FXII:Ag). Double-spun normal plasma was pooled, filled into siliconized glass ampoules, and freeze-dried to prepare the candidate material. Data from 20 laboratories using the one-stage clotting assay was used to assign the functional activity value in units (u). The antigen value was calculated using data from 8 laboratories that carried out antigen assays. Each laboratory was requested to collect two local normal plasma pools. Units of activity and antigen were calculated relative to these pools, as is usual for new coagulation factor analytes. The amount of activity or antigen in 1 ml of normal plasma from each pool was taken to be 1 unit. A total of 566 donors were used across the pools for the FXII:C study, and 216 donors for the FXII:Ag study.
The overall geometric mean per ampoule for FXII:C was 0.86 u and for FXII:Ag was 0.80 u. The inter-laboratory variation was 10 and 11%, respectively (expressed as geometric coefficient of variation). Based on these data, the candidate was deemed suitable for use as an IS for FXII. In 2017, the candidate was established by the World Health Organization (WHO) Expert Committee on Biological Standardization as the WHO 1st IS for blood coagulation factor XII, plasma (National Institute for Biological Standards and Control code 15/180). The values assigned were 0.86 international units (IU) of functional activity (FXII:C) per ampoule and 0.80 IU/ampoule of antigen (FXII:Ag).

Keywords: International Standard for factor XII, Factor XII functional activity, Factor XII antigen, Multicentre study, Measurement of factor XII

Received: 14 Nov 2017; Accepted: 07 Feb 2018.

Edited by:

Joost Meijers, University of Amsterdam, Netherlands

Reviewed by:

Owen McCarty, Oregon Health & Science University, United States
Thomas Renne, University Medical Center Hamburg-Eppendorf, Germany
Coen Maas, University Medical Center Utrecht, Netherlands  

Copyright: © 2018 Wilmot, Hockley, Rigsby and Gray. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Helen Wilmot, National Institute for Biological Standards and Control (NIBSC), Haemostasis Section, Potters Bar, Hertfordshire, United Kingdom, helen.wilmot@nibsc.org